Gilead to Buy Cancer Biotech Tubulis in $5B Deal

Bloomberg's Michelle Davis joins Dani Burger on "Bloomberg Deals." Gilead agreed to buy private German biotech Tubulis in a deal worth up to $5 billion as it looks to boost its portfolio in a hot new area of cancer drug development. (Source: Bloomberg)...

Redirecting to full article...